Medicamen Biotech Limited has achieved significant milestones in Q2 2024, including FDA and EU GMP approvals, expansion of its plants, and establishment of a new distribution subsidiary. The company has also appointed a new managerial team and filed its first ANDA for Bortezomib injection.